Antibiotic

Global Bird Flu Treatment Market Research Report to 2027 - Players Include Aurobindo Pharma, BioCryst Pharmaceuticals, Bristol-Myers Squibb and Chewy - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 6, 2022

What are the inhibiting factors and impact of COVID-19 shaping the Global Bird Flu Treatment Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Bird Flu Treatment Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Bird Flu Treatment Market?
  • What is the market share of the leading vendors in the Global Bird Flu Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Bird Flu Treatment Market?

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

Retrieved on: 
Wednesday, June 29, 2022

Initiating this pivotal Phase 2/3 trial marks an important step towards delivering a new treatment option to patients with treatment-refractory MAC lung disease, an area which has seen little innovation, said Eric Easom, President and Chief Executive Officer of AN2 Therapeutics.

Key Points: 
  • Initiating this pivotal Phase 2/3 trial marks an important step towards delivering a new treatment option to patients with treatment-refractory MAC lung disease, an area which has seen little innovation, said Eric Easom, President and Chief Executive Officer of AN2 Therapeutics.
  • As a once-daily oral therapy, epetraborole has the potential to become an important component of a multi-drug treatment regimen for patients with treatment-refractory MAC lung disease.
  • Epetraborole has been granted Qualified Infectious Disease Product and Fast Track status by the FDA for treatment-refractory MAC lung disease, as well as orphan drug designation for the treatment of infections caused by NTM.
  • This double-blind, placebo-controlled superiority trial uses an adaptive design to evaluate the safety and efficacy of epetraborole in patients with treatment-refractory MAC lung disease.

AMR Industry Alliance Launches Antibiotic Manufacturing Standard to Help Mitigate the Impacts of Antimicrobial Resistance

Retrieved on: 
Tuesday, June 14, 2022

Geneva, June 14, 2022 (GLOBE NEWSWIRE) -- The AMR Industry Alliance , the largest life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), today announced another groundbreaking step in driving responsible antibiotic manufacturing through the publication of its Antibiotic Manufacturing Standard: Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics.

Key Points: 
  • Geneva, June 14, 2022 (GLOBE NEWSWIRE) -- The AMR Industry Alliance , the largest life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), today announced another groundbreaking step in driving responsible antibiotic manufacturing through the publication of its Antibiotic Manufacturing Standard: Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics.
  • Our Alliances Standard launches the next chapter of responsible manufacturing throughout the global antibiotic value chain, said Thomas Cueni, Chair of the AMR Industry Alliance and Director General of the International Federation of Pharmaceutical Manufacturers and Associations.
  • The Standard marks the formalization of the Alliances 2018 Common Antibiotic Manufacturing Framework, which described a risk-based approach to assessing and controlling antibiotic manufacturing waste streams.
  • The AMR Industry Alliance engaged BSI, the business improvement and standards company, to provide expert services in relation to the development of this antibiotic manufacturing standard.

Signify Health Issues Quality and Social Impact Report

Retrieved on: 
Thursday, April 14, 2022

Signify Health , Inc. [NYSE: SGFY], a leading healthcare platform that leverages advanced analytics, technology and nationwide healthcare networks to create and power value-based payment programs, today announced the publication of its 2021 Quality and Social Impact Report.

Key Points: 
  • Signify Health , Inc. [NYSE: SGFY], a leading healthcare platform that leverages advanced analytics, technology and nationwide healthcare networks to create and power value-based payment programs, today announced the publication of its 2021 Quality and Social Impact Report.
  • Signifys more than 600 social care coordinators screen individuals for social issues that affect their ability to access quality healthcare and achieve the best possible health outcome.
  • As a result of these efforts, in 2021, Signify connected more than 260,000 people with services to address social determinants of health (SDOH) issues such as food insecurity, social isolation, and transportation.
  • To learn more about Signify Health and the initiatives it is undertaking to lead the industry forward and drive quality and social impact, view the report here .

The Global Antibiotics Market Will Grow to USD 59,253.24 Million by 2028, at a CAGR of 3.76% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 15, 2022

The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.

Key Points: 
  • The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.
  • The growing prevalence of bacterial infection is one of the major factors increasing the demand for antibiotics globally.
  • Such potential increase in prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period.
  • Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others.

EmeritusDX Announces Launch of UTIDX™ to Advance Patient Care in Urology

Retrieved on: 
Friday, January 28, 2022

"We are proud to launch UTIDX and feel strongly about the value this test will bring to our clients.

Key Points: 
  • "We are proud to launch UTIDX and feel strongly about the value this test will bring to our clients.
  • The turnaround time for UTIDX is 24-48 hours compared to traditional microbiology that has a 3-5 day turnaround time.
  • "There has been a substantial gap in patient care for quite some time and we are excited to provide this solution" added Embree.
  • We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients

Retrieved on: 
Tuesday, January 25, 2022

SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based medicines deploying its proprietary and patent-protected CRISPR/Casplatform.

Key Points: 
  • SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based medicines deploying its proprietary and patent-protected CRISPR/Casplatform.
  • The company applies its CRISPR technologies to selectively target microbial pathogens and remodel the microbiome to address important unmet medical needs.
  • SNIPR BIOME is pioneering a novel use of CRISPR/Castechnology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient's microbial community intact.
  • SNIPR BIOME was recently awarded a grant by CARB-X of up to 10.2m USD for CRISPR-based treatment ofhaematologicalcancer patients at risk of neutropenic fever and life-threating infections (SNIPR001).

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients

Retrieved on: 
Tuesday, January 25, 2022

SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based medicines deploying its proprietary and patent-protected CRISPR/Casplatform.

Key Points: 
  • SNIPR BIOME is engaged in the discovery and development of CRISPR/Cas-based medicines deploying its proprietary and patent-protected CRISPR/Casplatform.
  • The company applies its CRISPR technologies to selectively target microbial pathogens and remodel the microbiome to address important unmet medical needs.
  • SNIPR BIOME is pioneering a novel use of CRISPR/Castechnology to selectively and precisely eradicate target bacteria, while leaving the rest of the patient's microbial community intact.
  • SNIPR BIOME was recently awarded a grant by CARB-X of up to 10.2m USD for CRISPR-based treatment ofhaematologicalcancer patients at risk of neutropenic fever and life-threating infections (SNIPR001).

Global Animal Growth Promoters and Performance Enhancers Market Analytics and Opportunity Outlook 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 15, 2021

Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising animal epidemics and climate change.

Key Points: 
  • Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising animal epidemics and climate change.
  • The non-antibiotic growth promoters and performance enhancers segment accounted for the largest share of the animal growth promoters and performance enhancers market in 2020.
  • Based on animal type, the poultry segment accounted for the largest share of the global animal growth promoters and performance enhancers market.
  • It aims at estimating the market size and future growth potential of the global animal growth promoters and performance enhancers market and different segments such as type, animal type and region.

Palette Life Sciences Celebrates Twenty Years of Deflux Treatment for Vesicoureteral Reflux (VUR) in the United States

Retrieved on: 
Tuesday, November 9, 2021

SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, Inc., a fully integrated life sciences company dedicated to improving patient outcomes, today announced the 20th anniversary of Deflux in the United States, the only FDA-approved minimally invasive, highly effective treatment for vesicoureteral reflux (VUR).

Key Points: 
  • SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, Inc. , a fully integrated life sciences company dedicated to improving patient outcomes, today announced the 20th anniversary of Deflux in the United States , the only FDA-approved minimally invasive, highly effective treatment for vesicoureteral reflux (VUR).
  • Deflux has been widely used as a minimally invasive treatment for VUR ever since, providing a highly effective, non-surgical treatment alternative to long-term antibiotics.
  • Deflux was available through Nestl Skin Health until 2018, when Palette Life Sciences entered into an agreement with Nestl Skin Health to license worldwide commercialization and development rights for Deflux.
  • Intermediate to long-term follow-up indicates low risk of recurrence after double hit endoscopic treatment for primary vesicoureteral reflux.